A Bill to Establish Federal Standards Regulating Medical False Advertising to Protect Public Health (NSDA Congress 2026)

Orientation. The chamber will want to debate “should we crack down on false medical advertising and snake oil” — and on that question the advocates win in a walk, because nobody stands up to defend health fraud. But that is not what this bill decides. The Federal Trade Commission already prohibits false and misleading health advertising under existing law, using the exact substantiation standard the bill names. So the real question is narrower and sharper: does this bill add anything to current law — and if so, is the new part the one genuinely useful fix (restoring a penalty power the FTC lost at the Supreme Court in 2021) or an overbroad speech restriction that treats unproven claims as if they were false? The advocate who knows the AMG hole has a real point; the opponent who only shouts “redundant” will lose to them. Control whether the round is about stopping fraud or about what this text actually does, and you control the room.

Part I — The Policy Pro/Con Brief

Why this debate is live right now

The thing the bill describes is already illegal. The FTC enforces against false and misleading health advertising under Sections 5 and 12 of the FTC Act, and its Health Products Compliance Guidance requires health claims to be backed by “competent and reliable scientific evidence” — the same “substantiated scientific evidence” the bill defines. The FTC and FDA already split the work: the FTC polices advertising, the FDA polices labeling and prescription-drug promotion.

What is genuinely unsettled is the FTC’s power to punish. In AMG Capital Management v. FTC (2021), a unanimous Supreme Court held the FTC cannot obtain monetary relief — restitution or disgorgement — under Section 13(b), stripping the agency of its main tool to claw back money from deceptive marketers. Justice Breyer’s opinion invited the FTC to “ask Congress to grant it further remedial authority,” and bills have since tried. So there is a real, current enforcement gap — but it is remedial, not substantive.

And the First Amendment bounds any expansion. In POM Wonderful, LLC v. FTC (2015), the D.C. Circuit applied the Central Hudson commercial-speech test and upheld the FTC’s power to require scientific substantiation, but struck down a rigid two-clinical-trial rule as more extensive than necessary. Regulating health-claim speech is constitutional, but only with a “reasonable fit” between the rule and the harm.

The Case FOR the Bill (Pros)

The advocates’ best ground is that health fraud causes real harm, that the FTC’s enforcement teeth were knocked out in 2021, and that statute can both restore them and lock the standard in.

1. Health fraud is a real and ongoing harm. Misleading claims about treatments, devices, and supplements lead people to waste money and forgo effective care, so a strong federal deterrent protects public health, not just wallets.

2. The AMG gap is real and this is aimed at it. Since the Supreme Court stripped the FTC’s monetary-relief power in 2021, deceptive marketers often keep their profits. Granting the FTC “expanded authority to issue civil penalties” targets exactly the hole the Court left — the bill’s genuine substantive contribution.

3. Codifying the standard makes it durable. Today’s “competent and reliable scientific evidence” requirement lives in FTC guidance, which an administration can rewrite; putting it in statute insulates it from rollback.

4. The FTC is the right agency. Naming the existing advertising regulator as primary authority centralizes enforcement rather than fragmenting it across new bodies.

5. Corrective disclosures are a speech-friendly remedy. Requiring a company to correct the record adds truthful information instead of banning speech, which is the kind of remedy that survives Central Hudson scrutiny.

6. The public-health timing is strong. Health misinformation is a front-and-center concern, so even a partly symbolic federal statement of standards carries deterrent and signaling value.

The Case AGAINST the Bill (Cons)

The opponents’ best ground is that the bill is redundant where it’s clear and unconstitutional where it’s new, and that it doesn’t actually perform the one fix that would justify it.

1. It is largely redundant. The FTC already prohibits false and misleading medical advertising using the same substantiation standard, so most of the bill restates law already on the books.

2. The definition is constitutionally overbroad. Defining “false or materially misleading” to include any claim that “lacks substantiated scientific evidence” conflates false with unproven, sweeping in truthful-but-not-yet-proven speech — the kind of overreach POM Wonderful and Central Hudson limit.

3. It is too vague to actually fix AMG. “Expanded authority to issue civil penalties” never amends Section 13(b) or specifies the mechanism the Supreme Court said was missing, so it may not accomplish the very thing that gives it a reason to exist.

4. It ignores the FDA. The bill names only the FTC, but the FDA regulates prescription-drug advertising and labeling; Section 4’s “all laws in conflict are null and void” could scramble the existing FTC–FDA division of authority the system depends on.

5. “Enhanced standards” is undefined. The bill promises enhanced federal standards but never says what is enhanced beyond current law, so enforcers receive no new substantive guidance — only a louder restatement.

6. It risks chilling legitimate speech. A hard “lacks substantiation” trigger can deter truthful claims about emerging science and burden small sellers who can’t fund full clinical trials, shrinking useful information rather than just fraud.

7. It over-claims and under-delivers. Pairing “establish enhanced standards” with a sweeping null-and-void clause gestures at major change while concretely doing little — the worst of both worlds, symbolism with collateral risk.

How to Weigh It

The strongest pro is that health fraud is real, the FTC’s penalty power was genuinely gutted in 2021, and statute could both restore it and harden the standard. The strongest con is that the FTC already prohibits exactly this conduct, that the bill’s text neither clearly performs the AMG fix nor respects the First Amendment line POM drew, and that its definition treats unproven claims as false.

The crux is what this bill actually is: redundant symbolism, a real restoration of lost FTC penalty power, or an overbroad speech restriction. If the room reads it as “stop snake oil,” advocates win on sympathy. If opponents show the FTC already does the substantive work, that the remedial gap the bill gestures at is left unfixed by the text, and that the definition is unconstitutionally broad, opponents win. Advocates must hang the bill on the AMG point and argue the text restores penalties. Opponents must concede the AMG gap is real, then prove this text doesn’t close it and oversteps where it’s new.

Source List (grouped by theme)

Existing FTC authority and the substantiation standard

• FTC — Health Claims (Sections 5 and 12; FTC/FDA division of authority)

• FTC — Health Products Compliance Guidance (”competent and reliable scientific evidence”)

The remedial gap

• CRS — AMG Capital Management v. FTC: FTC cannot obtain monetary relief under Section 13(b)

First Amendment / commercial speech

• POM Wonderful, LLC v. FTC, D.C. Cir. (2015) — substantiation upheld under Central Hudson; two-RCT floor struck

Part II — Congressional Debate Bill Analysis

What the bill does

The bill directs the United States to establish “enhanced” federal standards prohibiting demonstrably false or materially misleading medical advertising, defines medical advertising, false/misleading claims, and substantiated scientific evidence, and names the FTC as primary enforcer with “expanded authority” to investigate, levy civil penalties, and mandate corrective disclosures. It takes effect October 1, 2026, and voids conflicting laws. The factual baseline both sides start from: the FTC already holds and exercises this authority under Sections 5 and 12 with this substantiation standard, and the one thing it genuinely lost — monetary relief under Section 13(b), gone after AMG in 2021 — is a remedial gap the bill’s text only gestures at.

The strongest case for the bill

The advocates’ best ground is that fraud is real, the FTC’s teeth were knocked out in 2021, and statute can fix and lock things in — so lead with the AMG gap, the point most of the chamber won’t know.

The first argument is the remedial gap. Since the Supreme Court stripped the FTC’s monetary-relief power in AMG, deceptive health marketers often keep their gains, and the bill’s expanded civil-penalty authority is aimed squarely at restoring that lost deterrent.

The second argument is the harm. Misleading claims about treatments and supplements push people toward useless products and away from effective care, so a strong federal deterrent is a public-health measure, not merely consumer protection.

The third argument is durability. The “competent and reliable scientific evidence” standard currently lives in FTC guidance that an administration can revise; codifying it in statute protects it from being weakened.

The fourth argument is institutional fit. Naming the FTC, the existing advertising regulator, as primary authority centralizes enforcement instead of creating a new and overlapping body.

The fifth argument is the remedy design. Corrective disclosures add truthful information rather than ban speech, the kind of remedy that survives Central Hudson review, so the bill leans on a constitutionally safe tool.

The sixth argument is timing. Health misinformation is a salient public concern, so a federal statement of standards carries deterrent and signaling value even where it overlaps existing law.

The strongest case against the bill

The opponents’ best ground is that the bill is redundant where clear and unconstitutional where new — lead with redundancy, then the overbreadth, then the failure to actually fix AMG.

The first and sharpest argument is the currency check: the bill recreates authority the FTC already has. The agency already prohibits false and misleading medical advertising under the same substantiation standard, so the substantive core is a restatement.

The second argument is the constitutional catch, the procedural objection most of the chamber will miss. Defining “false or materially misleading” to include claims that merely “lack substantiated scientific evidence” treats unproven as false, sweeping in protected truthful speech that POM Wonderful and Central Hudson shield.

The third argument is that the bill doesn’t do its own best justification. “Expanded authority to issue civil penalties” never amends Section 13(b), the provision AMG gutted, so the text may fail to restore the monetary relief that is the only thing it could usefully add.

The fourth argument is the missing FDA. The bill names only the FTC while the FDA governs prescription-drug ads and labeling, and Section 4’s null-and-void clause could disrupt the established FTC–FDA division.

The fifth argument is that “enhanced standards” is undefined: the bill never states what is enhanced beyond current law, so it hands enforcers a louder restatement, not new guidance.

The sixth argument is the chilling effect: a hard “lacks substantiation” trigger deters truthful emerging-science claims and burdens small sellers who can’t fund clinical trials, shrinking useful information along with the fraud.

Cross-examination questions

Questions for advocates to ask opponents.

• “Do you dispute that misleading health claims cause real harm to consumers — yes or no?”

• “After AMG Capital in 2021, the FTC can’t claw back money from deceptive marketers. Isn’t restoring that power exactly what’s needed?”

• “Today’s substantiation standard sits in revisable guidance. What’s wrong with locking it into statute?”

• “Corrective disclosures add information rather than ban speech — what’s your First Amendment objection to that remedy?”

• “If the FTC already does this, why has health misinformation kept spreading? Isn’t stronger penalty authority the missing piece?”

• “If your concern is the definition, isn’t that an amendment to tighten language, not a reason to kill the bill?”

Questions for opponents to ask advocates.

• “The FTC already prohibits false medical advertising under Sections 5 and 12. What does this bill make illegal that isn’t already?”

• “Your definition covers claims that ‘lack substantiated scientific evidence.’ Is an unproven claim the same thing as a false one — yes or no?”

• “POM Wonderful struck down a rigid substantiation rule on First Amendment grounds. How does your definition survive Central Hudson?”

• “The power the FTC actually lost was monetary relief under Section 13(b). Where in this bill is Section 13(b) amended?”

• “The FDA regulates prescription-drug ads and labeling. Why does your bill name only the FTC?”

• “Section 4 voids ‘all laws in conflict.’ Does that wipe out the existing FTC and FDA authority you’re relying on?”

• “What does the word ‘enhanced’ add? Point me to one new standard in the text that the FTC doesn’t already apply.”

• “How does a small seller with a truthful but un-trialed claim avoid penalty under your ‘lacks substantiation’ language?”

Drafting and definitional traps

The bill’s text rewards close reading and punishes the drafter.

The definition in Section 2(B) is disjunctive and overbroad: a claim is sanctionable if it is “demonstrably inaccurate, lacks substantiated scientific evidence, or misrepresents clinical effectiveness.” The middle prong treats unproven as false, the precise overreach POM Wonderful curtailed.

“Expanded authority to issue civil penalties” in Section 3 is undefined and doesn’t amend anything. The FTC already has civil-penalty authority for violations of rules and orders; the power it lost in AMG was equitable monetary relief under Section 13(b), which this text never names — so the bill’s marquee fix may not be in the bill.

“Enhanced federal standards” in Section 1 is never specified. The bill asserts enhancement without stating a single standard that differs from current FTC practice.

The bill names only the FTC and is silent on the FDA, which regulates prescription-drug advertising and labeling — so the allocation of authority over Rx promotion is left unresolved.

Section 4’s “all laws in conflict are hereby declared null and void,” in a field built on the interlocking FTC Act and FDA statutes, is not decorative here — it could be read to void parts of the very framework the bill depends on.

The October 1, 2026 effective date comes with no transition period for the FTC to write rules or for advertisers to comply.

Logical flaws

The deepest problem is a redundancy non-sequitur. The bill’s premise is that false medical advertising goes unregulated; its conclusion is a new federal standard — but the FTC already regulates it, so the premise (a substantive gap) doesn’t support the conclusion, because the real gap is remedial, not substantive.

A category error is baked into the definition. Treating any claim that “lacks substantiated scientific evidence” as “false or misleading” conflates not proven true with proven false — two different things — so the operative definition mislabels a whole class of lawful speech as deceptive.

There is a means-end mismatch. If the goal is to restore the penalty power AMG removed, the instrument should amend Section 13(b); “establish enhanced standards” addresses a substantive problem that doesn’t exist while leaving the remedial one the text gestures at unsolved.

The null-and-void clause is self-undermining. Voiding “all laws in conflict” can erase the FTC and FDA authority the bill relies on to function, so the enforcement scheme can knock out its own foundation.

And the constitutional premise is unsound. The bill assumes all unsubstantiated health claims can be treated as sanctionable falsity, but POM Wonderful and Central Hudson require a reasonable fit — so the rule, as written, cannot constitutionally do what it claims.

Verdict / how to play it

The chamber will saturate the advocate side. “Stop fake medical claims” is easy applause, and most competitors will run the public-health frame without ever noticing the FTC already does this. Expect several speeches that treat the bill as if false health advertising were currently legal.

This bill is unusual, though: the prepared advocate has a genuine, current, non-obvious point in AMG, and the lazy opponent who only says “redundant” will lose to them. The rare and more valuable opposition speech concedes the AMG gap is real, then shows the text doesn’t actually fix it and is unconstitutional where it’s new.

If you are advocating, do not pretend the FTC does nothing — concede the overlap and pivot hard to AMG: the FTC lost its money power in 2021, this restores the penalty teeth, and corrective disclosures keep the remedy First Amendment-safe. Frame the bill as enforcement restoration, not invention.

If you are opposing, the highest-leverage move is the one-two: the FTC already prohibits this conduct under Sections 5 and 12, and the bill’s one new idea — treating unproven claims as false — is the overreach POM Wonderful struck down. Then close the escape hatch: the penalty power the FTC actually lost was Section 13(b) monetary relief, and this text never amends Section 13(b), so it is redundant where it’s clear and unconstitutional where it’s new. Hold the FDA-silence and null-and-void points for when an advocate insists the bill is carefully drafted.

Do not let the round collapse into “do you support false advertising,” which the advocates win; force it onto “does this bill add anything lawful that current law doesn’t already do,” which the opponents win. One cross-apply: the “agency already holds this authority” redundancy frame and the Central Hudson commercial-speech limit transfer to any bill in the docket that expands a regulator that already has the power or restricts speech to reach a harm existing law already covers.